Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13216378 | 0.86 | AR (0.64) | AR | |
| SCHEMBL12812528 | 0.82 | AR (0.60) | ARPGR | |
| SCHEMBL25330095 | 0.80 | AR (0.45) | ARPGR | |
| SCHEMBL31131413 | 0.80 | AR (0.45) | ARPGR | |
| SCHEMBL324996 | 0.79 | AR (0.57) | AR | |
| SCHEMBL1291612 | 0.79 | AR (0.57) | ARPGR | |
| SCHEMBL2693449 | 0.77 | AR (0.47) | AR | |
| SCHEMBL24508330 | 0.77 | AR (0.50) | ARPGR | |
| SCHEMBL15421833 | 0.77 | AR (0.42) | ARPGR | |
| SCHEMBL17806029 | 0.77 | AR (0.32) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-11001556-B2 | Crystalline forms | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-05-11 | — | — | US | disclosed |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-11-19 | — | — | US | disclosed |
| US-20200308113-A1 | CRYSTALLINE FORMS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-10-01 | — | — | US | disclosed |
| US-20200270210-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED | 2020-08-27 | — | — | US | disclosed |
| US-10730831-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2020-08-04 | — | — | US | disclosed |
| US-10562852-B2 | Crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-02-18 | — | — | US | disclosed |
| US-20190040006-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-02-07 | — | — | US | disclosed |
| US-10196353-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED | 2010-10-07 | — | — | US | disclosed |
| EP-2222636-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | Ligand Pharmaceuticals Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009082437-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
| WO-2009105214-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105214-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009082437-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, IGF1R | AR 1/4885PGR 16/4885 |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885PGR 92/4885 |
| US-20200270210-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885 |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885PGR 97/4885 |
| US-11001556-B2 | Crystalline forms | SHBG, NR5A1, AR | AR 3/4885PGR 177/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | AR 1/4885PGR 82/4885 |
| US-20200308113-A1 | CRYSTALLINE FORMS | SHBG, NR5A1, AR | AR 3/4885PGR 177/4885 |
| US-20190040006-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885PGR 92/4885 |
| US-10196353-B2 | Chemical compounds | AR, NR5A1, ESRRA | AR 1/4885PGR 49/4885 |
| US-10730831-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | AR 1/4885PGR 82/4885 |
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | AR 1/4885PGR 28/4885 |
| US-10562852-B2 | Crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile | AR, NR5A1, SHBG | AR 1/4885PGR 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.